trending Market Intelligence /marketintelligence/en/news-insights/trending/aYjp4tk4qf5za6tELoiEvA2 content esgSubNav
In This List

Celgene's bowel disease treatment demonstrates efficacy in phase 2 trials

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Celgene's bowel disease treatment demonstrates efficacy in phase 2 trials

Celgene Corp. said its anti-inflammatory drug Ozanimod, or RPC1063, showed benefit in patients with Crohn's disease and ulcerative colitis.

In the phase 2 STEPSTONE study, 43% of the patients using Ozanimod saw a 25% decrease in Crohn's disease, while 27% of patients saw a reduction of 50% after 12 weeks.

In the phase 2 TOUCHSTONE study, 91% of ulcerative colitis patients at week 92 had little or no active disease. The most common adverse effects were ulcerative colitis flare, anemia, upper respiratory tract infection and back pain.

The results will be presented at the 2017 World Congress of Gastroenterology in Orlando, Fla.